Payment overview · 2025
General Payments
$470.90
28 reported records · 7 companies
Healthcare provider profile · identity verified
Sherry Bragg
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · PINEVILLE, WV · NPI 1942673843
Verified facts
What the public records show
CMS Open Payments records show Sherry Bragg received $470.90 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 44.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $207.42 | 44.0% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $140.19 | 29.8% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.77 | 11.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.70 | 4.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.92 | 3.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.90 | 3.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.00 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $470.90 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $193.99 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $179.81 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $117.45 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.45 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 173 | 52 |
| Omeprazole | Omeprazole | 165 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 144 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 130 | 48 |
| Gabapentin | Gabapentin | 130 | 43 |
| Montelukast Sodium | Montelukast Sodium | 117 | 56 |
| Lisinopril | Lisinopril | 112 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 107 | 41 |
| Cefdinir | Cefdinir | 100 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 31 |
| Potassium Chloride | Potassium Chloride | 98 | 39 |
| Ibuprofen | Ibuprofen | 97 | 61 |
| Famotidine | Famotidine | 94 | 32 |
| Tramadol Hcl | Tramadol Hcl | 86 | 29 |
| Metformin Hcl | Metformin Hcl | 85 | 29 |
| Lorazepam | Lorazepam | 79 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 77 | 27 |
| Azithromycin | Azithromycin | 77 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 28 |
| Fluconazole | Fluconazole | 73 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 23 |
| Losartan Potassium | Losartan Potassium | 70 | 23 |
| Furosemide | Furosemide | 69 | 27 |
| Ozempic | Semaglutide | 67 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 14 |
| Meloxicam | Meloxicam | 53 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 52 | 14 |
| Simvastatin | Simvastatin | 51 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 28 |
| Trazodone Hcl | Trazodone Hcl | 39 | 11 |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 29 |
| Bupropion Xl | Bupropion Hcl | 36 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | 14 |
| Nystatin | Nystatin | 35 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 12 |
| Ibu | Ibuprofen | 33 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 11 |
| Estradiol | Estradiol | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 13 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Valsartan | Valsartan | 29 | 12 |
| Glimepiride | Glimepiride | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Cephalexin | Cephalexin | 27 | 23 |
| Alprazolam | Alprazolam | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 21 |
| Pregabalin | Pregabalin | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | 11 |
| Linzess | Linaclotide | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 17 |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | 14 |
| Brilinta | Ticagrelor | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 16 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 14 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 12 |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $470.90 · 28 records | Novo Nordisk Inc | AIRSUPRA, FARXIGA, FREESTYLE LIBRE 2, LINZESS, Ohtuvayre, Ozempic, PAXLOVID, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error